Opendata, web and dolomites

SELNET SIGNED

Sarcoma as a model to improve diagnosis and clinical care of rare tumors through a European and Latin American multidisciplinary network

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SELNET project word cloud

Explore the words cloud of the SELNET project. It provides you a very rough idea of what is the project "SELNET" about.

networks    strategic    poor    conduct    life    pathological    brazil    rica    therapies    collaborative    community    patients    biobanks    prognostic    expert    soft    reference    risk    observational    diagnosis    validating    france    cancers    clinical    scarcity    registry    latin    core    groups    incorrect    replicable    diagnoses    cancer    absence    peru    hence    cancersrare    hindered    survival    data    medical    group    costa    lack    mexico    heterogeneous    prognosis    financial    care    delayed       threatening    drivers    relapse    sarcoma    creation    accounting    argentina    guidelines    rare    incidence    appropriate    model    22    selnet    sarcomas    referral    trials    bone    multidisciplinary    intercontinental    caribbean    healthcare    worsen    american    drugs    improvement    italy    10    patient    complete    education    adult    barrier    translational    countries    deaths    unavailability    preclinical    boards    pathologists    celac    quality    solid    rcs    network    international    centers    death    mtbs    create    spain    tumors    tissues    models    malignancies    30    practitioners    adherence    cpgs    tumor    representing    policies    specialists    expertise    subtypes   

Project "SELNET" data sheet

The following table provides information about the project.

Coordinator
SERVICIO ANDALUZ DE SALUD 

Organization address
address: AVENIDA DE LA CONSTITUCION 18
city: SEVILLA
postcode: 41071
website: http://www.sas.junta-andalucia.es/principal/default.asp

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙294˙306 €
 EC max contribution 3˙092˙400 € (94%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SERVICIO ANDALUZ DE SALUD ES (SEVILLA) coordinator 792˙000.00
2    CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD FR (LYON) participant 486˙000.00
3    FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI IT (Milan) participant 450˙000.00
4    ISTITUTO ORTOPEDICO RIZZOLI IT (BOLOGNA) participant 432˙000.00
5    GRUPO ESPANOL DE INVESTIGACION EN SARCOMAS ASOCIACION ES (MADRID) participant 306˙000.00
6    ALEXANDER FLEMING SA AR (BUENOS AIRES) participant 194˙400.00
7    FUNDACION AMOR ESPERANZA Y VIDA CR (HEREDIA) participant 180˙000.00
8    INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-INEN PE (LIMA) participant 176˙400.00
9    SARCOMA PATIENTS EURONET EV DE (WOLFERSHEIM) participant 75˙600.00
10    FUNDACAO ANTONIO PRUDENTE BR (SAO PAULO) participant 0.00
11    Instituto Nacional de Cancerología MX (MEXICO) participant 0.00

Map

 Project objective

Rare cancersRare cancers are associated with poor survival, accounting for 22% of new cancer diagnoses in Europe, and 30% of cancer deaths. Sarcomas are a heterogeneous group of life-threatening rare solid malignancies affecting soft and bone tissues, representing 10% of rare tumors and around 2% of adult tumors, with an incidence of 5.9/100,000/year in Europe. Appropriate management of sarcoma patients is hindered by the absence of referral policies to reference centers (RCs), incorrect or delayed diagnosis, non-adherence of therapies to clinical practice guidelines (CPGs), and lack of expertise by practitioners, which increases the risk of relapse and death. These problems worsen in the Community of Latin American and Caribbean States (CELAC) due to the scarcity or complete unavailability of RCs, expert pathologists, multidisciplinary tumor boards (MTBs), new cancer drugs, clinical trials, patient registry data, and financial resources. Hence, the SELNET project seeks to create a European and Latin American multidisciplinary network of clinical and translational specialists to improve diagnosis and clinical care in sarcomas, with the aim of validating a collaborative model replicable in other rare tumors and in other countries. Recognized cancer centers and research groups of Spain, Italy, France, Mexico, Brazil, Argentina, Costa Rica, and Peru will contribute to better rare cancer care by fostering RCs, healthcare barrier analysis, CPGs, and medical education as key improvement drivers. The core of the research work focuses on improving diagnosis and prognosis of sarcoma patients through the creation of pathological diagnosis networks, MTBs, the conduct of an international registry-based observational study to assess clinical management quality and prognostic factors, and the implementation of an strategic translational research program to develop intercontinental sarcoma biobanks, preclinical models, and a translational study with drugs in rare sarcoma subtypes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SELNET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SELNET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More